Regen BioPharma (Regen BioPharma) Total Assets : $0.14 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Total Assets?

Regen BioPharma's Total Assets for the quarter that ended in Mar. 2024 was $0.14 Mil.

During the past 3 years, the average Total Assets Growth Rate was 23.70% per year. During the past 5 years, the average Total Assets Growth Rate was 23.10% per year.

During the past 11 years, Regen BioPharma's highest 3-Year average Total Assets Growth Rate was 294.20%. The lowest was -43.30%. And the median was 23.70%.

Total Assets is connected with ROA %. Regen BioPharma's annualized ROA % for the quarter that ended in Mar. 2024 was -324.25%. Total Assets is also linked to Revenue through Asset Turnover. Regen BioPharma's Asset Turnover for the quarter that ended in Mar. 2024 was 0.39.

Regen BioPharma Total Assets Historical Data

The historical data trend for Regen BioPharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Total Assets Chart

Regen BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Assets

Get a 7-Day Free Trial

0.10

0.12

1.21

0.56

0.35

Regen BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															-	0.29	0.35	0.16	0.14

Regen BioPharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Regen BioPharma's Total Assets for the fiscal year that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (A: Sep. 2023 )	+	Total Liabilities (A: Sep. 2023 )
	=	-5.104	+	5.458
	=	0.35

Regen BioPharma's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	-5.176	+	5.317
	=	0.14

Regen BioPharma (OTCPK:RGBP) Total Assets Explanation

Total Assets is connected with ROA %.

Regen BioPharma's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-0.488	/	( (0.16	+	0.141)	/ 2 )
	=	-0.488	/	0.1505
	=	-324.25 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Regen BioPharma's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0.059	/	( (0.16	+	0.141)	/ 2 )
=	0.059	/	0.1505
=	0.39

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Regen BioPharma Total Assets Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma (Regen BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.